Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Novel Adenoviral Vector Targets Tumor Blood Vessel Endothelial Cells

By BiotechDaily International staff writers
Posted on 07 Jan 2014
Image: A case where a primary kidney tumor spread to an ovary: The vectors gathering in the metastatic tumor vessels glow green. The red staining shows the normal blood vessels of the ovary (Photo courtesy of Dr. David T. Curiel and Dr. Jeffrey M. Arbeit, Washington University School of Medicine).
Image: A case where a primary kidney tumor spread to an ovary: The vectors gathering in the metastatic tumor vessels glow green. The red staining shows the normal blood vessels of the ovary (Photo courtesy of Dr. David T. Curiel and Dr. Jeffrey M. Arbeit, Washington University School of Medicine).
Researchers working with mouse cancer models used a novel gene-therapy approach to demonstrate the potential for directing therapeutic agents specifically to tumor blood vessels while avoid interaction with the liver or other normal tissues.

Investigators at the Washington University School of Medicine (St. Louis, MO, USA) used a first-generation, inactivated adenoviral (Ad5) vector to transport three kb (kilobases) of the human roundabout4 (ROBO4) enhancer/promoter gene transcriptionally complexed to an enhanced green fluorescent protein (EGFP) reporter.

Robo4 is an endothelial cell-specific member of the Roundabout axon guidance receptor family that specifically binds to UNC5B, a vascular Netrin receptor. Robo4 maintains blood vessel integrity by activating UNC5B, which inhibits signaling downstream of vascular endothelial growth factor (VEGF).

In the current study, which was published in the December 23, 2013, online edition of the journal PLOS ONE, the investigators intravenously injected the Ad/ROBO4/green fluorescent vector into immunodeficient mice bearing 786-O renal cell carcinoma subcutaneous (SC) xenografts and kidney orthotopic (KO) tumors.

Results revealed that Ad5ROBO4 directed enhanced green fluorescent protein expression to the tumor neovasculature, whereas a vector whose reporter was controlled by the human Cytomegalovirus (CMV) enhancer/promoter produced sporadic endothelial cell reporter expression in only one or two vessels throughout the tumors.

“We do not want to kill tumor vessels,” said senior author Dr. Jeffrey M. Arbeit, professor of urologic surgery, cell biology, and physiology at the Washington University School of Medicine. “We want to hijack them and turn them into factories for producing molecules that alter the tumor microenvironment so that it no longer nurtures the tumor. This could stop the tumor growth itself or cooperate with standard chemotherapy and radiation to make them more effective. One advantage of this strategy is that it could be applied to nearly all of the most common cancers affecting patients.”

Related Links:

Washington University School of Medicine



Channels

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 

Events

21 Apr 2015 - 23 Apr 2015
21 Apr 2015 - 23 Apr 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.